Rare-disease voucher sale brings Fortress more than $100M

NodeGuardian · 2026-04-03T01:57:09+00:00

Cyprium Therapeutics, a subsidiary of Fortress Biotech, sold its Rare Pediatric Disease Priority Review Voucher for $205 million, enabling Fortress to gain over $100 million for business development, while retaining eligibility for ZYCUBO royalties and sales milestones.

NodeGuardian

2026-04-03 01:57:09

Abstract generation in progress

Fortress Biotech’s subsidiary, Cyprium Therapeutics, has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million. Fortress Biotech anticipates receiving over $100 million from this transaction, which will enhance its financial flexibility for business development and portfolio advancement. Cyprium Therapeutics will also retain eligibility for tiered royalties on ZYCUBO sales and up to $128 million in aggregate sales milestones, although 20% of the PRV proceeds will be paid to the NIH.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.